Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Plasmablastic Lymphoma 1 Lymphomatoid Granulomatosis 1 Lymphoma, Primary Effusion 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, B-Cell 1 Glioblastoma 1 Gallbladder Neoplasms 1 Cholangiocarcinoma 1 Burkitt Lymphoma 1

Interventions

Temozolomide 41 Radiotherapy 19 Radiation 12 Nivolumab 10 pembrolizumab 8 Magnetic Resonance Spectroscopy 8 Bevacizumab 7 Specimen Handling 6 poly ICLC 4 atezolizumab 4 Lomustine 4 Ipilimumab 4 Surgical Procedures, Operative 3 Photons 3 Immunoglobulin G 3 Disulfides 3 Cyclophosphamide 3 veliparib 2 sargramostim 2 rocakinogene sifuplasmid 2 olaparib 2 niraparib 2 Transurethral Resection of Bladder 2 Surveys and Questionnaires 2 Standard of Care 2 Radiotherapy, Intensity-Modulated 2 Radiosurgery 2 OKN 007 2 Mycophenolic Acid 2 Metformin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Glioblastoma × varlilumab × Clear all

NCT03688178 2026-05-22

DERIVe

Duke University

Phase 2 Active not recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡